Cansortium Past Earnings Performance
Past criteria checks 0/6
Cansortium has been growing earnings at an average annual rate of 20.5%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 23.5% per year.
Key information
20.5%
Earnings growth rate
31.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 23.5% |
| Return on equity | n/a |
| Net Margin | -18.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Slammed 29% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch
Dec 27
Cansortium Inc. (CSE:TIUM.U) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 07Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt
Oct 25Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward
Sep 04Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 21Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch
Jul 11Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story
Jan 15Is Cansortium (CSE:TIUM.U) Using Too Much Debt?
Nov 30Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?
Sep 01Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
Jul 28An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued
Mar 08Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?
Jan 09Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden
Sep 09Revenue & Expenses Breakdown
How Cansortium makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 104 | -20 | 38 | 0 |
| 30 Jun 24 | 103 | -13 | 36 | 0 |
| 31 Mar 24 | 100 | -20 | 34 | 0 |
| 31 Dec 23 | 97 | -23 | 31 | 0 |
| 30 Sep 23 | 95 | -36 | 29 | 0 |
| 30 Jun 23 | 92 | -36 | 28 | 0 |
| 31 Mar 23 | 90 | -34 | 26 | 0 |
| 31 Dec 22 | 88 | -37 | 26 | 0 |
| 30 Sep 22 | 83 | -15 | 27 | 0 |
| 30 Jun 22 | 76 | -2 | 27 | 0 |
| 31 Mar 22 | 70 | -24 | 27 | 0 |
| 31 Dec 21 | 65 | -19 | 30 | 0 |
| 30 Sep 21 | 62 | -31 | 32 | 0 |
| 30 Jun 21 | 61 | -47 | 33 | 0 |
| 31 Mar 21 | 57 | -28 | 35 | 0 |
| 31 Dec 20 | 52 | -37 | 32 | 0 |
| 30 Sep 20 | 47 | -48 | 35 | 0 |
| 30 Jun 20 | 40 | -51 | 35 | 0 |
| 31 Mar 20 | 33 | -51 | 35 | 0 |
| 31 Dec 19 | 29 | -53 | 41 | 0 |
| 30 Sep 19 | 24 | -54 | 41 | 0 |
| 30 Jun 19 | 19 | -13 | 39 | 0 |
| 31 Mar 19 | 14 | -9 | 33 | 0 |
| 31 Dec 18 | 8 | 0 | 21 | 0 |
| 30 Sep 18 | 3 | 16 | 14 | 0 |
| 30 Jun 18 | 0 | -15 | 9 | 0 |
| 31 Mar 18 | 0 | -16 | 8 | 0 |
| 31 Dec 17 | 0 | -10 | 8 | 0 |
Quality Earnings: TIUM.U is currently unprofitable.
Growing Profit Margin: TIUM.U is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TIUM.U is unprofitable, but has reduced losses over the past 5 years at a rate of 20.5% per year.
Accelerating Growth: Unable to compare TIUM.U's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TIUM.U is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: TIUM.U's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 21:00 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cansortium Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Stanley | Beacon Securities Limited |
| Jonathan DeCourcey | BTIG |
| Robert Burleson | Canaccord Genuity |